Aviragen Therapeutics (AVIR) Misses Q1 EPS by 1c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q1 EPS of ($0.57), $0.01 worse than the analyst estimate of ($0.56).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Deutsche Bank cuts Novo Nordisk to Sell after earnings, shares dip
• Exlservice (EXLS) PT Raised to $45; TD Cowen: 'Outperformance Is Becoming Harder To Ignore'
• Okta, Inc (OKTA) PT Raised to $143 at Bernstein SocGen Group